KEAP1 and hepatocellular carcinoma: ANK domain targeting may slow the course of HCC and liver damage.<h4>Conclusions</h4>Targeting the NOTCH1-KEAP1-NRF2 axis as a possible chronic hepatic injury therapy is supported by these findings, which identify NOTCH1-KEAP1 as an NRF2 suppressor that accelerates the progression of liver injury.